Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

被引：1
|
作者：
Joensuu, H.
Eriksson, M.
Hatrmann, J.
Hall, K. Sundby
Schutte, J.
Reichardt, A.
Schlemmer, M.
Wardelmann, E.
Ramadori, G.
Al-Batran, S.
Nilsson, B. E.
Monge, O.
Kallio, R.
Sarlomo-Rikala, M.
Bono, P.
Leinonen, M.
Hohenberger, P.
Alvegard, T.
Reichardt, P.
机构：
[1] Univ Helsinki, Cent Hosp, Helsinki, Finland
[2] Univ Lund Hosp, S-22185 Lund, Sweden
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Oslo Univ Hosp, Oslo, Norway
[5] Marien Hosp Duesseldorf, Dusseldorf, Germany
[6] HELIOS Klinikum Berlin Buch, Sarcoma Ctr Berlin Brandenburg, Berlin, Germany
[7] Univ Munich, Univ Hosp Grosshadern, Munich, Germany
[8] Univ Bonn, Bonn, Germany
[9] Univ Gottingen, D-37073 Gottingen, Germany
[10] Krankenhaus NW Frankfurt, Frankfurt, Germany
[11] Sahlgrens Univ Hosp, Gothenburg, Sweden
[12] Haukeland Hosp, Oslo, Norway
[13] Oulu Univ Hosp, Oulu, Finland
[14] Helsinki Univ Hosp, Helsinki, Finland
[15] 4Pharma, Turku, Finland
[16] Univ Klinikum Mannheim, Mannheim, Germany
[17] Lund Univ, Lund, Sweden
[18] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
    Joensuu, H.
    Eriksson, M.
    Hatrmann, J.
    Hall, K. Sundby
    Schutte, J.
    Reichardt, A.
    Schlemmer, M.
    Wardelmann, E.
    Ramadori, G.
    Al-Batran, S.
    Nilsson, B. E.
    Monge, O.
    Kallio, R.
    Sarlomo-Rikala, M.
    Bono, P.
    Leinonen, M.
    Hohenberger, P.
    Alvegard, T.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial
    Joensuu, Heikki
    Eriksson, Mikael
    Hall, Kirsten Sundby
    Reichardt, Annette
    Ramadori, Giuliano
    Hohenberger, Peter
    Al-Batran, Salah-Eddin
    Schlemmer, Marcus
    Bauer, Sebastian
    Pink, Daniel
    Duyster, Justus
    Nilsson, Bengt E.
    Monge, Odd R.
    Kallio, Raija
    Bono, Petri
    Junnila, Jouni
    Wardelmann, Eva
    Alvegard, Thor
    Reichardt, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
    Reichardt, P.
    Hartmann, J. T.
    Hall, K. Sundby
    Eriksson, M.
    Schuette, J.
    Ramadori, G.
    Hohenberger, P.
    Duyster, J.
    Leinonen, M.
    Joensuu, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 15 - 15
  • [4] Multicentre randomized phase II trial of adjuvant imatinib for 6 versus 12 months in patients with intermediate or high risk GIST: Interim analysis results
    Yamamoto, K.
    Kurokawa, Y.
    Tsujinaka, T.
    Muguruma, K.
    Nakai, T.
    Fujita, J.
    Hiramatsu, M.
    Takabayashi, A.
    Hirota, S.
    Nishida, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S625 - S625
  • [5] Randomized phase II study of 6 versus 12 months of adjuvant imatinib for patients with intermediate- or high-risk GIST
    Muguruma, Kazuya
    Kurokawa, Yukinori
    Tsujinaka, Toshimasa
    Fujita, Junya
    Nakai, Takuya
    Takabayashi, Arimichi
    Hiramatsu, Masako
    Terashima, Masanori
    Iwasaki, Yoshiki
    Hasegawa, Junichi
    Kira, Toshihiko
    Shimokawa, Toshio
    Hirota, Seiichi
    Nishida, Toshirou
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Phase II trial of Neoadjuvant/Adjuvant imatinib mesylate (IM) for advanced primary and recurrent operable GI stromal tumor (GIST) - early results of RTOG 0132
    Eisenberg, B. L.
    Harris, J.
    Blanke, C.
    Demetri, G.
    Von Mehren, M.
    Heinrich, M.
    Watson, J.
    Okuno, S.
    Kane, J.
    Hoffman, J.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 26 - 26
  • [7] Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.
    Corrie, Philippa
    Marshall, Andrea
    Lorigan, Paul
    Gore, Martin Eric
    Tahir, Saad
    Faust, Guy
    Kelly, Charles G.
    Marples, Maria
    Danson, Sarah
    Marshall, Ernest
    Houston, Stephen
    Board, Ruth E.
    Waterston, Ashita Marie
    Nobes, Jenny Penelope
    Harries, Mark
    Kumar, Satish
    Young, Gemma
    Barker, Emily
    Dunn, Janet
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
    Nilsson, B.
    Sjolund, K.
    Kindblom, L-G
    Meis-Kindblom, J. M.
    Bumming, P.
    Nilsson, O.
    Andersson, J.
    Ahlman, H.
    BRITISH JOURNAL OF CANCER, 2007, 96 (11) : 1656 - 1658
  • [9] Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
    B Nilsson
    K Sjölund
    L-G Kindblom
    J M Meis-Kindblom
    P Bümming
    O Nilsson
    J Andersson
    H Ahlman
    British Journal of Cancer, 2007, 96 : 1656 - 1658
  • [10] Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665
    Eisenberg, Burton L.
    Harris, Jonathan
    Blanke, Charles D.
    Demetri, George D.
    Heinrich, Michael C.
    Watson, James C.
    Hoffman, John P.
    Okuno, Scott
    Kane, John M.
    von Mehren, Margaret
    JOURNAL OF SURGICAL ONCOLOGY, 2009, 99 (01) : 42 - 47
12345